- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AstraZeneca Has a Promising Oncology Pipeline
AstraZeneca's Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.
AstraZeneca’s Phase III pipeline is growing ahead of plan, chief executive Pascal Soriot told a recent media briefing, and cancer drugs make up a major chunk of the pipeline.
In oncology, olaparib for solid tumours, moxetumomab pasudotox for hairy cell leukaemia and selumetinib for non-small cell lung cancer are expected to be key players. Also showing potential are AZD9291 a ‘third generation’ tyrosine kinase inhibitor for NSCLC, and from AstraZeneca’s biologics R&D arm MedImmune, MEDI4736, a PD-L1 monoclonal antibody that is being studied in patients with advanced solid tumours.
Within AZ’s oncology franchise, the breast cancer portfolio has been targeted for expansion and a raft of new combination therapies is under investigation,. However substantial growth is expected from established agents such as Faslodex (fulvestrant).
Read the full story at:
http://bit.ly/P1u39eSource: PharmaTimes
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
